Integra LifeSciences Holdings Corp Stock
A loss of -1.830% shows a downward development for Integra LifeSciences Holdings Corp.
Our community is currently low on Integra LifeSciences Holdings Corp with 1 Buy predictions and 4 Sell predictions.
A slightly negative potential of -6.54% at a current price of 10.7 € for Integra LifeSciences Holdings Corp is the result of a target price of 10 €.
Pros and Cons of Integra LifeSciences Holdings Corp in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Cons
?
S********** s********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Integra LifeSciences Holdings Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Integra LifeSciences Holdings Corp | -1.830% | -4.464% | -2.727% | -52.655% | 0.943% | -78.812% | -81.062% |
| Icu Medical Inc. | 0.750% | 3.876% | 8.943% | -16.770% | 8.065% | -16.770% | -23.864% |
| Bio-Rad Labs Inc. A | -1.890% | -3.677% | 3.888% | -20.215% | 3.606% | -36.592% | -47.089% |
| Merit Medical Systems | 1.450% | -1.408% | -4.762% | -29.293% | -5.405% | 10.236% | 50.215% |
Comments
Integra LifeSciences (NASDAQ:IART) had its price target lowered by analysts at Citigroup Inc. from $12.00 to $11.00. They now have a "sell" rating on the stock.
Show more
Ratings data for IART provided by MarketBeat
Integra LifeSciences (NASDAQ:IART) had its price target raised by analysts at JPMorgan Chase & Co. from $12.00 to $13.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for IART provided by MarketBeat
Integra LifeSciences (NASDAQ:IART) had its "sell" rating reaffirmed by analysts at Citigroup Inc..
Show more
Ratings data for IART provided by MarketBeat
News
Integra (IART) Q2 Revenue Beats by 5%
Integra LifeSciences (NASDAQ:IART), a medical technology company specializing in neurosurgery, reconstructive, and tissue technologies, released its results for Q2 2025 on July 31, 2025. The most
